Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- VIMIAN.ST
- Price
- 37.90
- Stock movement up
- +1.22 (3.33%)
- Company name
- Vimian Group AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Diagnostics & Research
- Market cap
- 19.62B
- Ent value
- 19.97B
- Price/Sales
- 55.69
- Price/Book
- 29.37
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 76653.93
- Forward P/E
- 331.29
- PEG
- -
- EPS growth
- -
- 1 year return
- 12.97%
- 3 year return
- -15.23%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-15
DIVIDENDS
VIMIAN.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 76653.93 |
| Price to OCF | 385.18 |
| Price to FCF | 549.18 |
| Price to EBITDA | 388.10 |
| EV to EBITDA | 395.03 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 55.69 |
| Price to Book | 29.37 |
| EV to Sales | 56.68 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 517.77M |
| EPS (TTM) | 0.00 |
| FCF per share (TTM) | 0.07 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 352.39M |
| Gross profit (TTM) | 246.72M |
| Operating income (TTM) | 39.38M |
| Net income (TTM) | 256.00K |
| EPS (TTM) | 0.00 |
| EPS (1y forward) | 0.11 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 70.01% |
| Operating margin (TTM) | 11.18% |
| Profit margin (TTM) | 0.07% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 39.17M |
| Net receivables | 53.77M |
| Total current assets | 267.36M |
| Goodwill | 506.55M |
| Intangible assets | 199.65M |
| Property, plant and equipment | 34.96M |
| Total assets | 1.06B |
| Accounts payable | 23.68M |
| Short/Current long term debt | 251.43M |
| Total current liabilities | 93.59M |
| Total liabilities | 389.79M |
| Shareholder's equity | 668.25M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 50.95M |
| Capital expenditures (TTM) | 15.21M |
| Free cash flow (TTM) | 35.73M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 0.04% |
| Return on Assets | 0.02% |
| Return on Invested Capital | 0.03% |
| Cash Return on Invested Capital | 3.92% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 37.84 |
| Daily high | 38.02 |
| Daily low | 36.76 |
| Daily Volume | 414K |
| All-time high | 117.16 |
| 1y analyst estimate | 48.03 |
| Beta | 1.60 |
| EPS (TTM) | 0.00 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 30 Apr 2025 |
Downside potential
Loading...
Downside potential data
| VIMIAN.ST | S&P500 | |
| Current price drop from All-time high | -67.65% | -12.04% |
| Highest price drop | -82.86% | -56.47% |
| Date of highest drop | 13 Oct 2023 | 9 Mar 2009 |
| Avg drop from high | -62.14% | -11.07% |
| Avg time to new high | 80 days | 12 days |
| Max time to new high | 941 days | 1805 days |
COMPANY DETAILS
Marketcap
19.62B
Marketcap category
Large-cap
Description
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.
Employees
1100
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
In April 2025, European markets are grappling with significant volatility as higher-than-expected U.S. tariffs have led to sharp declines across major indices, including the STOXX Europe 600 Index whi...
April 10, 2025
As European markets navigate the complexities of U.S. trade tariffs and fluctuating monetary policies, the pan-European STOXX Europe 600 Index recently experienced a slight decline, reflecting broader...
March 19, 2025
As European markets navigate the complexities of U.S. trade tariffs and monetary policy uncertainties, investors are keenly observing how these macroeconomic factors might influence growth opportuniti...
March 18, 2025
As global markets continue to navigate the complexities of rising inflation and shifting trade policies, U.S. stock indexes are nearing record highs, with growth stocks outperforming their value count...
February 17, 2025
As global markets continue to navigate a landscape marked by rising inflation and fluctuating interest rates, U.S. stock indexes are climbing toward record highs, with growth stocks outperforming valu...
February 17, 2025
As global markets navigate a choppy start to 2025, marked by inflation concerns and political uncertainties, investors are keenly watching for opportunities amid fluctuating indices. With U.S. equitie...
January 16, 2025
As global markets navigate mixed signals with U.S. stocks closing out a strong year despite recent slumps, and economic indicators like the Chicago PMI pointing to potential challenges ahead, investor...
January 8, 2025
As global markets navigate a period of economic uncertainty marked by rate cuts from central banks and mixed performances across major indices, growth stocks continue to demonstrate resilience, with t...
December 18, 2024
As global markets show resilience with U.S. indexes nearing record highs and positive sentiment buoyed by strong labor market data, investors are keenly observing potential undervalued stock opportuni...
November 28, 2024
In November 2024, global markets are experiencing a notable upswing, with U.S. indices reaching record highs following the Republican "red sweep" in the elections, which has fueled optimism around pot...
November 13, 2024
Next page